Adolor stops testing Entereg for OBD; Charles River to add 60 jobs in SC;

> To conserve cash, Adolor said it would stop trying to broaden the use of Entereg to cover chronic obstructive bowel disorder; the drug already is approved to treat post-operative ileus. Release | Report

>  Charles River Laboratories plans to invest $20 million to build a research center and warehouse in Charleston, SC, and create an estimated 60 jobs. Report

> Pharmaceutical Product Development plans to expand its contract research operations into Ahtlone, Ireland, investing up to $18 million in a new facility and creating around 250 jobs. Report

> Scolr Pharma said Daniel Wilds has resigned as CEO of the company and as a member of its board of directors, and that until a new CEO is named, the company will be run by its current executive management team. Report l Chutes and Ladders

> China Aoxing Pharmaceutical, which specializes in pain meds, said it won a new Chinese production license for Ligustrazine Phosphate injection for treatment of ischemic stroke. Release

> Abbott Laboratories has forged a deal to buy a unit of Isis Pharmaceuticals for $175 million--on top of a $40 million investment it made earlier this year. Report

> Noted Deutsche Bank analyst Barbara Ryan says that Pfizer is likely to make a major play to establish itself in biotechnology, with a bid for Amgen likely. Report

> Neurobiological Technologies started to sharpen the budget axe after halting enrollment in late-stage clinical trials for its lead drug to treat acute ischemic stroke. Report

> In a significant verdict for developers forging a path to more personalized medicines, FDA advisers say that drug companies will need to do more studies and gather more data before they can win their case for targeting patients based on genetics. Report

> Dynavax Technologies has landed a $10 million upfront payment and up to $200 million in milestones for each of four development programs optioned by GlaxoSmithKline. Report

And Finally... Doctors worry that epilepsy patients might stop taking their meds precipitately, after an FDA warning that the drugs may be linked with suicidal thoughts and behaviors. Release